Setmelanotide
Also known as: BIM-22493, Imcivree, RM-493, RM‑493, Setmelanotide
Source Setmelanotide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Setmelanotide is a synthetic peptide that acts as a potent agonist of the melanocortin‑4 receptor (MC4R). It is approved for subcutaneous use in individuals with rare genetic forms of severe obesity, such as pro‑opiomelanocortin (POMC) or leptin‑receptor (LEPR) deficiency. By activating central pathways that regulate hunger and satiety, setmelanotide can produce clinically meaningful weight loss and reduce hyperphagia in these populations.
Mechanism of Action
Setmelanotide mimics the endogenous ligand α‑melanocyte‑stimulating hormone and binds with high affinity to MC4R, a key receptor in the hypothalamic leptin‑melanocortin pathway. Activation of MC4R triggers intracellular signaling that suppresses appetite, enhances satiety, and increases energy expenditure. The drug’s selective MC4R agonism restores signaling that is deficient in POMC or LEPR genetic disorders, thereby normalising feeding behaviour.
What the Research Shows
Narrative reviews (2023, 2025) highlight setmelanotide as the only approved therapy for rare genetic obesity syndromes. A phase‑3 open‑label trial in participants with POMC or LEPR deficiency (2020) reported 80% and 45% achieving ≥10% weight loss after one year, with hunger scores falling 27%–44%. Common adverse events were injection‑site reactions, hyperpigmentation, nausea and vomiting, but no serious treatment‑related events. A phase‑1b study (2017) showed weight loss in carriers of certain MC4R variants, and pre‑clinical work demonstrated superior potency over α‑MSH. Reviews note ongoing investigation in Prader‑Willi syndrome, but no approved indication there.
Reported Benefits
Clinical data demonstrate that setmelanotide can induce ≥10% body‑weight reduction in the majority of patients with POMC or LEPR deficiency, together with substantial reductions in self‑reported hunger. These effects translate into improved control of hyperphagia, better metabolic parameters, and enhanced quality of life for individuals with these rare disorders. The drug offers a targeted, mechanism‑based option where lifestyle measures alone are insufficient.
Limitations of the Evidence
Evidence stems from small, open‑label phase‑3 cohorts (10–11 participants per genotype) and a limited phase‑1b trial, restricting generalisability. Efficacy varies by genetic cause; MC4R‑deficient individuals showed modest weight loss compared with POMC‑deficient patients. Data are lacking for common obesity and for long‑term cardiovascular outcomes. Ongoing trials in Prader‑Willi syndrome have not yet demonstrated benefit, and the durability of weight loss beyond one year remains uncertain.
Safety Considerations
The most frequently reported adverse events across trials were injection‑site reactions and skin hyperpigmentation, reflecting MC4R activation in melanocytes. Gastrointestinal symptoms such as nausea and vomiting occurred in a minority of participants. No serious treatment‑related adverse events were recorded in the phase‑3 studies. Caution is advised in patients with pre‑existing skin disorders, and clinicians should monitor for pigmentary changes and injection‑site irritation.
How It Is Administered
Setmelanotide is supplied as a peptide formulation for subcutaneous injection. Clinical studies have used regular subcutaneous dosing, with the exact schedule (daily or weekly) determined by the prescribing clinician based on patient weight, age, and response. The drug is administered by injection into the abdomen, thigh, or upper arm using standard aseptic technique.
Routes of Administration
Goals & Uses
- Weight management in PCSK1 deficiency obesityObesity TreatmentHigh
- Investigational use in other MC4R pathway deficienciesMetabolic / ObesityModerate
- Weight reduction in Bardet-Biedl syndromeMetabolic / ObesityHigh
- Weight management in POMC deficiency obesityObesity TreatmentHigh
- Hyperphagia reductionMetabolic / Appetite ControlHigh
- Weight reduction in POMC/PCSK1/LEPR deficiency obesityMetabolic / ObesityHigh
- Weight management in LEPR deficiency obesityObesity TreatmentHigh
Contraindications
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Hypersensitivity to setmelanotide or excipientsAllergyHigh
- Hypersensitivity to setmelanotideAllergicHigh
- Use in obesity not caused by POMC/PCSK1/LEPR deficiency or BBSOff Label UseModerate
Adverse Effects
- Depression/suicidal ideationPsychiatricUncommon
- Injection site reactionsLocalCommon
- Sexual adverse reactionsSexual/ReproductiveUncommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- Skin hyperpigmentationDermatologicCommon
- Spontaneous penile erectionsSexual/ReproductiveCommon
- HyperpigmentationDermatologicCommon
- DiarrheaGastrointestinalUncommonLoose or frequent stools
Drug Interactions
- Medications affecting glucose homeostasisLow
- Other melanocortin receptor agonistsModerate
- Serotonergic agents (e.g., SSRIs)Low
- OpioidsLow
Population Constraints
- PregnancyReproductive SafetyRelative
- Children under 6 yearsPediatricAbsolute
- Children under 2 yearsPediatricAbsolute
- Severe hepatic impairmentOrgan ImpairmentRelative
- Renal impairment (severe)RenalRelative
Regulatory Status
- European UnionApprovedApproved: Obesity due to POMC deficiency, Obesity due to PCSK1 deficiency, Obesity due to LEPR deficiencyEMA approval 2021.
- United StatesApprovedApproved: Obesity due to POMC deficiency, Obesity due to PCSK1 deficiency, Obesity due to LEPR deficiencyApproved 2020 as Imcivree.
- United KingdomApprovedApproved: Obesity due to POMC deficiency, Obesity due to PCSK1 deficiency, Obesity due to LEPR deficiencyApproved via MHRA 2021.
FDA‑approved (2020) as Imcivree; EMA‑approved (2021) for the same genetic obesity indications.
Evidence & Sources
- Journal ArticleModerateFredrick TW, Camilleri M, Acosta A2025-01-01T00:00:00.000000Z
- Journal ArticleModerateChakhtoura M, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleModerateMahmoud R, Kimonis V, Butler MG2023-01-01T00:00:00.000000Z
- Journal ArticleModerateClément K, et al.2020-01-01T00:00:00.000000Z
- Journal ArticleModerateFaccioli N, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleModerateCollet TH, et al.2017-01-01T00:00:00.000000Z
Frequently Asked Questions
What genetic conditions is setmelanotide approved to treat?
Setmelanotide has received regulatory approval for the treatment of severe obesity caused by pathogenic variants in the pro‑opiomelanocortin (POMC) gene or the leptin‑receptor (LEPR) gene, both of which disrupt the melanocortin pathway and lead to uncontrolled appetite.
How does setmelanotide reduce hunger?
The peptide binds to and activates the melanocortin‑4 receptor in the hypothalamus, mimicking the action of α‑MSH. This signaling suppresses appetite, enhances satiety, and promotes energy expenditure, thereby lowering the drive to eat.
What side effects should patients expect?
The most common adverse effects reported in trials are mild injection‑site reactions, skin hyperpigmentation, nausea, and occasional vomiting. No serious treatment‑related events were observed, but patients should be monitored for skin changes and gastrointestinal discomfort.
Is setmelanotide useful for common obesity?
Current evidence supports efficacy only in rare genetic forms of obesity (POMC or LEPR deficiency). Its benefit in the broader population with common obesity has not been established and is not an approved indication.
How is the medication given?
Setmelanotide is administered as a subcutaneous injection. The dosing interval (e.g., daily or weekly) is individualized by the treating physician based on the patient’s age, weight, and therapeutic response.
What is Setmelanotide?
Setmelanotide is a synthetic peptide that acts as a potent agonist of the melanocortin‑4 receptor (MC4R). It is approved for subcutaneous use in individuals with rare genetic forms of severe obesity, such as pro‑opiomelanocortin (POMC) or leptin‑receptor (LEPR) deficiency. By activating central pathways that regulate hunger and satiety, setmelanotide can produce clinically meaningful weight loss and reduce hyperphagia in these populations.
What is Setmelanotide used for?
Setmelanotide is educationally associated with: Weight management in PCSK1 deficiency obesity, Investigational use in other MC4R pathway deficiencies, Weight reduction in Bardet-Biedl syndrome, Weight management in POMC deficiency obesity, Hyperphagia reduction, Weight reduction in POMC/PCSK1/LEPR deficiency obesity, Weight management in LEPR deficiency obesity. Educational only — not medical advice.
How is Setmelanotide administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Setmelanotide?
Reported adverse effects include: Depression/suicidal ideation, Injection site reactions, Sexual adverse reactions, Nausea, Skin hyperpigmentation, Spontaneous penile erections, Hyperpigmentation, Diarrhea. This list is not exhaustive — consult a qualified clinician.
Who should avoid Setmelanotide?
Recorded contraindications: Pregnancy, Hypersensitivity to setmelanotide or excipients, Hypersensitivity to setmelanotide, Use in obesity not caused by POMC/PCSK1/LEPR deficiency or BBS. Consult a qualified clinician before use.